SuperworthTrevi Therapeutics market cap TRVI
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $1.8B
- Highest close in our data
- $2.7B
- Jul 2026
Trevi Therapeutics is worth $1.8B at the close on Oct 23, 2026, at $12.61 a share.
That is up 40% over the last year and up 6979% over five years.
Its highest close in our data was $2.7B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.8B | $1.3B | $2.7B | +9% |
| 2025 | $1.6B | $289M | $1.7B | +402% |
| 2024 | $328.2M | $84.3M | $328.2M | +284% |
| 2023 | $85.6M | $70.9M | $206.6M | −26% |
| 2022 | $115.7M | $12.9M | $175.8M | +472% |
| 2021 | $20.2M | $17.9M | $62.3M | −55% |
| 2020 | $44.5M | $41M | $135.8M | −33% |
| 2019 | $66.3M | $49.6M | $152.8M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Trevi Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| TRVITrevi Therapeutics | $1.8B |
| ANIPANI Pharmaceuticals | $1.7B |
| PAHCPhibro Animal Health | $1.6B |
| HRMYHarmony Biosciences | $2.1B |
| ANABAnaptysbio | $1.5B |
| PCRXPacira BioSciences | $1.5B |
| PBHPrestige Consumer Healthcare | $2.3B |
| OMEROmeros | $1.2B |
| NRIXNurix Therapeutics | $2.8B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OGNOrganon | $3.6B |
| Peer median | $1.6B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Trevi Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.